capravirine

Capravirine is a small molecule non-nucleoside reverse transcriptase inhibitor (NNRTI) that was developed for the treatment of HIV infection, particularly in patients who had failed existing antiretroviral therapies. It acts by binding directly to HIV-1 reverse transcriptase, causing structural changes that inhibit both RNA- and DNA-dependent polymerase activity, thereby blocking viral replication. Capravirine demonstrated a unique resistance profile in preclinical studies, showing activity against both wild-type HIV and strains with mutations conferring resistance to other NNRTIs, such as K103N. The drug reached phase II/III clinical trials but was discontinued after studies failed to show significant advantages over standard triple-drug regimens. Capravirine was originally developed by Shionogi and later by Pfizer[1][3][4][5].

Other names

capravirine